Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected].

Non-small cell lung cancer (NSCLC) is the most common cancer and the leading cause of death from cancer worldwide. Antiangiogenic strategies directed towards tumor stroma are becoming gold standard in NSCLC treatment and researchers have been searching for biomarkers to identify patients for whom th...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ana L Coelho, António Araújo, Mónica Gomes, Raquel Catarino, Agostinho Marques, Rui Medeiros
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2014
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f4bc05cdbb10491bb67f27f480e0b850
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f4bc05cdbb10491bb67f27f480e0b850
record_format	dspace
spelling	oai:doaj.org-article:f4bc05cdbb10491bb67f27f480e0b8502021-11-18T08:30:26ZCirculating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected].1932-620310.1371/journal.pone.0090009https://doaj.org/article/f4bc05cdbb10491bb67f27f480e0b8502014-01-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24587185/?tool=EBIhttps://doaj.org/toc/1932-6203Non-small cell lung cancer (NSCLC) is the most common cancer and the leading cause of death from cancer worldwide. Antiangiogenic strategies directed towards tumor stroma are becoming gold standard in NSCLC treatment and researchers have been searching for biomarkers to identify patients for whom therapy with antiangiogenic inhibitors may be most beneficial and the importance of these as prognostic factors in NSCLC. The purpose of this study was to evaluate the prognostic value of circulating Ang-2 mRNA levels prior to treatment in NSCLC patients. The mRNA levels were determined by quantitative real-time PCR in the peripheral blood of 92 NSCLC patients. Our results demonstrate that patients with high circulating Ang-2 mRNA levels have diminished overall survival when compared to those with low mRNA levels (20.3 months vs 34.3 months, respectively; Log Rank Test, p = 0.016), when considering all NSCLC stages and this difference is even bigger when considering only patients with stage IV (15.9 months vs 31.3 months, respectively; Log Rank Test, p = 0.036). Moreover, circulating Ang-2 mRNA levels independently determine overall survival, and the concordance (c) index analysis showed that the definition of a nomogram that contains information regarding tumor stage, patients' smoking status and circulating Ang-2 mRNA levels present an increased capacity to predict overall survival in NSCLC patients (c-index 0.798). These results suggest that this nomogram could serve as a unique and practical tool to determine prognosis in NSCLC, not relying on the availability of adequate surgical or biopsy specimens of NSCLC. Attending to our results, the circulating Ang-2 mRNA levels should also be included in the design of preclinical studies and clinical trials involving antiangiogenic drugs targeting Ang-2, to guide adequate patient stratification and dose selection and increasing the likelihood of benefit to a level that is acceptable to patients and clinicians.Ana L CoelhoAntónio AraújoMónica GomesRaquel CatarinoAgostinho MarquesRui MedeirosPublic Library of Science (PLoS)articleMedicineRScienceQENPLoS ONE, Vol 9, Iss 2, p e90009 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Ana L Coelho António Araújo Mónica Gomes Raquel Catarino Agostinho Marques Rui Medeiros Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected].
description	Non-small cell lung cancer (NSCLC) is the most common cancer and the leading cause of death from cancer worldwide. Antiangiogenic strategies directed towards tumor stroma are becoming gold standard in NSCLC treatment and researchers have been searching for biomarkers to identify patients for whom therapy with antiangiogenic inhibitors may be most beneficial and the importance of these as prognostic factors in NSCLC. The purpose of this study was to evaluate the prognostic value of circulating Ang-2 mRNA levels prior to treatment in NSCLC patients. The mRNA levels were determined by quantitative real-time PCR in the peripheral blood of 92 NSCLC patients. Our results demonstrate that patients with high circulating Ang-2 mRNA levels have diminished overall survival when compared to those with low mRNA levels (20.3 months vs 34.3 months, respectively; Log Rank Test, p = 0.016), when considering all NSCLC stages and this difference is even bigger when considering only patients with stage IV (15.9 months vs 31.3 months, respectively; Log Rank Test, p = 0.036). Moreover, circulating Ang-2 mRNA levels independently determine overall survival, and the concordance (c) index analysis showed that the definition of a nomogram that contains information regarding tumor stage, patients' smoking status and circulating Ang-2 mRNA levels present an increased capacity to predict overall survival in NSCLC patients (c-index 0.798). These results suggest that this nomogram could serve as a unique and practical tool to determine prognosis in NSCLC, not relying on the availability of adequate surgical or biopsy specimens of NSCLC. Attending to our results, the circulating Ang-2 mRNA levels should also be included in the design of preclinical studies and clinical trials involving antiangiogenic drugs targeting Ang-2, to guide adequate patient stratification and dose selection and increasing the likelihood of benefit to a level that is acceptable to patients and clinicians.
format	article
author	Ana L Coelho António Araújo Mónica Gomes Raquel Catarino Agostinho Marques Rui Medeiros
author_facet	Ana L Coelho António Araújo Mónica Gomes Raquel Catarino Agostinho Marques Rui Medeiros
author_sort	Ana L Coelho
title	Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected].
title_short	Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected].
title_full	Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected].
title_fullStr	Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected].
title_full_unstemmed	Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected].
title_sort	circulating ang-2 mrna expression levels: looking ahead to a new prognostic factor for nsclc [corrected].
publisher	Public Library of Science (PLoS)
publishDate	2014
url	https://doaj.org/article/f4bc05cdbb10491bb67f27f480e0b850
work_keys_str_mv	AT analcoelho circulatingang2mrnaexpressionlevelslookingaheadtoanewprognosticfactorfornsclccorrected AT antonioaraujo circulatingang2mrnaexpressionlevelslookingaheadtoanewprognosticfactorfornsclccorrected AT monicagomes circulatingang2mrnaexpressionlevelslookingaheadtoanewprognosticfactorfornsclccorrected AT raquelcatarino circulatingang2mrnaexpressionlevelslookingaheadtoanewprognosticfactorfornsclccorrected AT agostinhomarques circulatingang2mrnaexpressionlevelslookingaheadtoanewprognosticfactorfornsclccorrected AT ruimedeiros circulatingang2mrnaexpressionlevelslookingaheadtoanewprognosticfactorfornsclccorrected
_version_	1718421718936059904

Circulating Ang-2 mRNA expression levels: looking ahead to a new prognostic factor for NSCLC [corrected].

Ejemplares similares